February 26, 2014. Link here. Cowen and Company 34th Annual Healthcare Conference 26th Annual ROTH Conference AmpliPhi BioSciences Corporation (OTCBB: APHB), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that President and CEO, Philip Young will be presenting at the Cowen and Company 34^th Annual Healthcare Conference at the Boston Marriott […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2014-02-26 17:57:042018-01-06 17:57:27AmpliPhi to Present at Upcoming Healthcare Conferences
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2014-02-25 17:57:352018-01-06 17:57:56Bioxyne Ltd completes sale of HI-164OV program to Mariposa Health Ltd
7 January 2014: Analysis from leading healthcare fund manager BioScience Managers has highlighted the outstanding year for biotech stocks on the ASX in 2013 with an average gain of 53.6%* across the sector. These findings compare with the All Ordinaries index that increased by 14.7% over 2013 and theS&P/ASX 200 Health Care Index which increased 23.5% […]
Link to press release here. RICHMOND, VA, US, COLWORTH, UK and SYDNEY, AUSTRALIA, December, 16 2013 – AmpliPhi BioSciences Corporation (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has entered into a definitive stock purchase agreement to raise approximately $18 million in a […]
ASX announcement link here. Avita CFO Mr Tim Rooney appointed interim CEO following resignation of Managing Director and CEO William Dolphin. Ian MacPherson elected as interim board Chairman following resignation of Dalton Gooding as Chairman. Internal progress made to review company remuneration report.
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-12-11 17:48:402018-01-06 17:49:04Avita Medical Update to Shareholders
Link here. Pharmaceutical company Pharmaxis (ASX:PXS) today announced that the Scottish Medicines Consortium (SMC) has accepted Bronchitol® (mannitol dry powder for inhalation) for use by the National Health Service in Scotland. Bronchitol is licensed for the treatment of adult cystic fibrosis (CF) patients aged 18 years and above as an add-on therapy to best standard of […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-12-10 17:49:132018-01-06 17:49:53Scottish Medicines Consortium Accepts Bronchitol For Use In Cystic Fibrosis Patients
Announcement link here. ATLANTA, Dec. 5, 2013 (GLOBE NEWSWIRE) — Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the “Company”) today announced that it has commenced dosing patients in the Northern Hemisphere portion of its ongoing Phase 2, randomized, double blind, placebo controlled, parallel arm clinical trial of laninamivir octanoate (LANI). The trial, referred to as “IGLOO”, compares the safety […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-12-05 17:48:072018-01-06 17:48:37Biota Initiates Dosing in Phase 2 IGLOO Trial of LANI in the Northern Hemisphere
04 December, 2013. Link here. Leading veterinary biologic drug developer Nexvet Biopharma (Nexvet) today announced promising clinical data in support of its novel compound NV-01 for treating acute and chronic pain in dogs.
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2013-12-04 15:55:252018-01-06 17:56:02Nexvet unveils clinical data supporting its novel pain treatment for dogs
AmpliPhi to Present at Upcoming Healthcare Conferences
/in Armata Pharmaceuticals, Portfolio CompaniesFebruary 26, 2014. Link here. Cowen and Company 34th Annual Healthcare Conference 26th Annual ROTH Conference AmpliPhi BioSciences Corporation (OTCBB: APHB), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that President and CEO, Philip Young will be presenting at the Cowen and Company 34^th Annual Healthcare Conference at the Boston Marriott […]
Bioxyne Ltd completes sale of HI-164OV program to Mariposa Health Ltd
/in Portfolio CompaniesLink to press release here.
ASX BIOTECH STOCKS SURGE 54% IN 2013
/in BioSciences Managers7 January 2014: Analysis from leading healthcare fund manager BioScience Managers has highlighted the outstanding year for biotech stocks on the ASX in 2013 with an average gain of 53.6%* across the sector. These findings compare with the All Ordinaries index that increased by 14.7% over 2013 and theS&P/ASX 200 Health Care Index which increased 23.5% […]
Alchemia expands executive leadership team, appointing Thomas Liquard as Chief Operating Officer
/in Portfolio CompaniesASX announcement here.
AmpliPhi Biosciences Announces $18 Million Private Placement
/in Armata Pharmaceuticals, Portfolio CompaniesLink to press release here. RICHMOND, VA, US, COLWORTH, UK and SYDNEY, AUSTRALIA, December, 16 2013 – AmpliPhi BioSciences Corporation (OTCBB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has entered into a definitive stock purchase agreement to raise approximately $18 million in a […]
Avita Medical Update to Shareholders
/in Avita Medical, Portfolio CompaniesASX announcement link here. Avita CFO Mr Tim Rooney appointed interim CEO following resignation of Managing Director and CEO William Dolphin. Ian MacPherson elected as interim board Chairman following resignation of Dalton Gooding as Chairman. Internal progress made to review company remuneration report.
Scottish Medicines Consortium Accepts Bronchitol For Use In Cystic Fibrosis Patients
/in Destiny Pharma, Portfolio CompaniesLink here. Pharmaceutical company Pharmaxis (ASX:PXS) today announced that the Scottish Medicines Consortium (SMC) has accepted Bronchitol® (mannitol dry powder for inhalation) for use by the National Health Service in Scotland. Bronchitol is licensed for the treatment of adult cystic fibrosis (CF) patients aged 18 years and above as an add-on therapy to best standard of […]
Biota Initiates Dosing in Phase 2 IGLOO Trial of LANI in the Northern Hemisphere
/in Portfolio CompaniesAnnouncement link here. ATLANTA, Dec. 5, 2013 (GLOBE NEWSWIRE) — Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the “Company”) today announced that it has commenced dosing patients in the Northern Hemisphere portion of its ongoing Phase 2, randomized, double blind, placebo controlled, parallel arm clinical trial of laninamivir octanoate (LANI). The trial, referred to as “IGLOO”, compares the safety […]
Nexvet unveils clinical data supporting its novel pain treatment for dogs
/in Pharmamark, Portfolio Companies04 December, 2013. Link here. Leading veterinary biologic drug developer Nexvet Biopharma (Nexvet) today announced promising clinical data in support of its novel compound NV-01 for treating acute and chronic pain in dogs.
Pharmaxis – AGM presentation and results
/in Destiny Pharma, Portfolio CompaniesChairman’s Address to 2013 Annual General Meeting here. AGM outcome of resolutions here.